After the completion of this activity, the participant should be able to:
- Examine safety, efficacy, dosing, and administration of different therapies used for chronic inflammatory demyelinating polyneuropathy (CIDP)
- Analyze best practices for the transition from intravenous to subcutaneous immunoglobulin (IVIg to SCIG) among patients with CIDP
- Identify the role of clinical team members in monitoring therapy and optimizing the management of patients with CIDP
Speaker
Leslie Myers, PharmD, IgCP®
CE
Nursing 1 contact hour
ACPE 1 contact hour
Recertification
1 IgCN® / IgCP® Recertification Units